Please enable Javascript
Cecilia Brown
Associate Editor
Cecilia Brown is an Associate Editor for Blood Cancers Today.
Articles by Cecilia Brown
Study Compares Fractionated, Single-Dose Gemtuzumab Ozogamicin in Older Adults with AML
Cecilia Brown
Acute Myeloid Leukemia
|
September 21, 2023
The study was conducted because it was “uncertain whether a fractionated schedule provides additional benefit."
Read More
Is NPM1 MRD Status Prognostic in Patients with AML Receiving Venetoclax-Based Therapy?
Cecilia Brown
Acute Myeloid Leukemia
|
September 21, 2023
Researchers analyzed prognostic impact of NPM1 MRD in a real-world cohort of patients with NPM1-mutated AML.
Read More
Phase III Trial Evaluates Adding Gemtuzumab Ozogamicin to Chemotherapy in NPM1-Mutated AML
Cecilia Brown
Acute Myeloid Leukemia
|
September 21, 2023
The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population.
Read More
Can Novel Targeted Therapies Improve Outcomes for CRLF2-Rearranged B-ALL?
Cecilia Brown
Acute Lymphoblastic Leukemia
|
September 20, 2023
Researchers retrospectively analyzed treatment outcomes of 69 patients with relapsed or refractory CRLF2-rearranged B-ALL.
Read More
Study Suggests Link Between Aging, Low-Hypodiploid ALL
Cecilia Brown
Acute Lymphoblastic Leukemia
|
September 20, 2023
Low hypodiploidy “defines a rare subtype” of B-cell ALL with a “dismal outcome.”
Read More
Pretransplant MRD Status in Blood Linked with Post-HSCT Survival, Relapse in AML
Cecilia Brown
Acute Myeloid Leukemia
|
September 20, 2023
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
Read More
Get to Know ... Catherine Coombs, MD
Cecilia Brown
Chronic Lymphocytic Leukemia
|
September 20, 2023
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Read More
HeMonitor Study Shows Noninvasive Hemoglobin Measurement Is 'Feasible' in Heme Malignancies
Cecilia Brown
Myelodysplastic Syndromes
|
September 14, 2023
The proof-of-concept study showed that noninvasive hemoglobin measurement is “feasible,” but there were several ...
Read More
Enrollment Underway for Phase II Study of Oral HMA Plus Magrolimab in MDS
Cecilia Brown
Meeting News
|
September 14, 2023
One aim is to evaluate the efficacy of oral decitabine/cedazuridine and magrolimab in intermediate to HR MDS.
Read More
IV Treatment Associated with Higher Anxiety Than Oral Therapy in CLL
Cecilia Brown
Chronic Lymphocytic Leukemia
|
September 11, 2023
All patients included in the study required treatment and had not previously received psychiatric treatment.
Read More
Study Evaluates Safety of Long-Term Pirtobrutinib Administration in B-cell Malignancies
Cecilia Brown
Meeting News
|
September 11, 2023
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
Read More
Is Outpatient Administration of Liso-Cel Cost Efficient for Patients with CLL?
Cecilia Brown
Chronic Lymphocytic Leukemia
|
September 11, 2023
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Read More
Study Finds High Economic Burden in Patients with MPNs
Cecilia Brown
Meeting News
|
September 9, 2023
Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave.
Read More
REVIVE Trial Shows Rusfertide Provides ‘Sustained’ Hematocrit Control in Polycythemia Vera
Cecilia Brown
Myeloproliferative Neoplasms
|
September 9, 2023
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
Read More
COMMANDS Biomarker Analysis Explores Luspatercept Mechanism in LR-MDS
Cecilia Brown
Meeting News
|
September 9, 2023
Researchers sought to differentiate the mechanism of action of luspatercept from epoetin alfa.
Read More
Could Hepatitis B Infection Be a Predisposition For MCL?
Cecilia Brown
Mantle Cell Lymphoma
|
September 8, 2023
The patient cohort had median OS of 27 months and a five-year OS of 24.5%.
Read More
Jorge Cortes, MD, Receives Michael J. Keating Award at SOHO Meeting
Cecilia Brown
Meeting News
|
September 7, 2023
The award recognizes a SOHO member who has significantly contributed to the advancement of blood cancer care and research.
Read More
Jennifer Brown, MD, PhD, on CLL Highlights at the SOHO Annual Meeting
Cecilia Brown
Chronic Lymphocytic Leukemia
|
September 7, 2023
Dr. Brown shares what CLL news and session she's watching at the Eleventh Annual Meeting of SOHO.
View More
SOHO Announces Poster Award Winners at Eleventh Annual Meeting
Cecilia Brown
Meeting News
|
September 7, 2023
Multiple posters received awards from the Society during a ceremony held at the annual meeting.
Read More
SOHO President Dr. Jennifer Brown on Key Highlights of Eleventh Annual Meeting
Jennifer R. Brown, MD, PhD
Meeting News
|
September 6, 2023
SOHO President Jennifer Brown, MD, PhD, talks about why she chose personalized medicine as this year's theme.
View More
Load More